Astellas Pharma Inc. buy melinda
Start price
26.03.18
/
50%
€12.63
Target price
05.04.18
€12.98
Performance (%)
4.02%
End price
05.04.18
€12.99
Summary
This prediction ended on 05.04.18 with a price of €12.99. With a performance of 4.02%, the BUY prediction by melinda for Astellas Pharma Inc. closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Astellas Pharma Inc. | -0.245% | -0.245% | 28.259% | -12.482% |
| iShares Core DAX® | -1.875% | 2.861% | 18.863% | 63.672% |
| iShares Nasdaq 100 | -2.177% | 0.048% | 3.956% | 109.562% |
| iShares Nikkei 225® | -0.867% | 6.987% | 21.062% | 54.912% |
| iShares S&P 500 | -1.253% | 1.248% | 2.246% | 69.801% |
Comments by melinda for this prediction
In the thread Astellas Pharma Inc. diskutieren
SectorDrug Pharmaceuticals Agenda 28/03 Endgültige Dividende Detachment
Astellas Pharma Inc. und Seattle Genetics, Inc. (SGEN) haben bekannt gegeben, dass die US-amerikanische Gesundheitsbehörde Breakthrough Therapy für ein Antikörper-Wirkstoff-Konjugat, Vedotin-Konjugat, Patienten mit lokal fortgeschrittenem oder metastasierendem Urothelkarzinom, die zuvor behandelt wurden, gewährt hat Checkpoint-Inhibitoren.
Stopped prediction by melinda for Astellas Pharma Inc.
Astellas Pharma Inc.
Start price
Target price
Perf. (%)
€13.42
25.07.23
25.07.23
€16.00
25.07.24
25.07.24
-25.34%
26.07.24
26.07.24
Astellas Pharma Inc.
Start price
Target price
Perf. (%)
€45.42
17.11.13
17.11.13
€42.00
19.05.14
19.05.14
-81.45%
19.05.14
19.05.14
Astellas Pharma Inc.
Start price
Target price
Perf. (%)
€26.00
10.08.10
10.08.10
€33.00
10.02.11
10.02.11
12.27%
10.02.11
10.02.11